Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Naoto Wakabayashi, Shiro Watanabe, Takashige Abe, Junki Takenaka, Kenji Hirata, Rina Kimura, Keita Sakamoto, Nobuo Shinohara, Kohsuke Kudo
OBJECTIVE: To investigate the incidence of adverse events (AEs) following single and multiple administrations of I-131 metaiodobenzylguanidine (MIBG) therapy for inoperable pheochromocytomas and paragangliomas (PPGLs). METHODS: A single-center retrospective study was conducted on patients with inoperable PPGLs who underwent I-131 MIBG therapy between January 2000 and December 2020. A total of 28 patients with available electronic medical records were included. The treatment consisted of a single intravenous administration of 150 mCi (5...
April 24, 2024: Annals of Nuclear Medicine
#2
JOURNAL ARTICLE
Wenjie Wang, Zijian Wang, Zumin Chen, Manman Liang, Aiping Zhang, Haoyu Sheng, Mingyue Ni, Jianghua Yang
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with a high mortality rate. Differentiating between SFTS and hemorrhagic fever with renal syndrome (HFRS) is difficult and inefficient. Retrospective analysis of the medical records of individuals with SFTS and HFRS was performed. Clinical and laboratory data were compared, and a diagnostic model was developed based on multivariate logistic regression analyzes. Receiver operating characteristic curve analysis was used to evaluate the diagnostic model...
May 2024: Journal of Medical Virology
#3
JOURNAL ARTICLE
Jonathan D Mosley, John P Shelley, Alyson L Dickson, Jacy Zanussi, Laura L Daniel, Neil S Zheng, Lisa Bastarache, Wei-Qi Wei, Mingjian Shi, Gail P Jarvik, Elisabeth A Rosenthal, Atlas Khan, Alborz Sherafati, Iftikhar J Kullo, Theresa L Walunas, Joseph Glessner, Hakon Hakonarson, Nancy J Cox, Dan M Roden, Stephan G Frangakis, Brett Vanderwerff, C Michael Stein, Sara L Van Driest, Scott C Borinstein, Xiao-Ou Shu, Matthew Zawistowski, Cecilia P Chung, Vivian K Kawai
Polygenic variation unrelated to disease contributes to interindividual variation in baseline white blood cell (WBC) counts, but its clinical significance is uncharacterized. We investigated the clinical consequences of a genetic predisposition toward lower WBC counts among 89,559 biobank participants from tertiary care centers using a polygenic score for WBC count (PGSWBC ) comprising single nucleotide polymorphisms not associated with disease. A predisposition to lower WBC counts was associated with a decreased risk of identifying pathology on a bone marrow biopsy performed for a low WBC count (odds-ratio = 0...
April 22, 2024: Nature Communications
#4
JOURNAL ARTICLE
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis Paz-Ares, Paul A Bunn
PURPOSE: The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m2 every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m2 daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS)...
April 22, 2024: Journal of Clinical Oncology
#5
REVIEW
Yuxin Niu, Yunhui Liu, Lanyue Huang, Wei Liu, Qiuyu Cheng, Tingting Liu, Qin Ning, Tao Chen
Dabie Banda virus (DBV), a tick-borne pathogen, was first identified in China in 2009 and causes profound symptoms including fever, leukopenia, thrombocytopenia and multi-organ dysfunction, which is known as severe fever with thrombocytopenia syndrome (SFTS). In the last decade, global incidence and mortality of SFTS increased significantly, especially in East Asia. Though previous studies provide understandings of clinical and immunological characteristics of SFTS development, comprehensive insight of antiviral immunity response is still lacking...
2024: Frontiers in Immunology
#6
Nicole Ann E Villa, Dragos G Pausescu, Eduardo D Espiridion
Psychiatric polypharmacy involves the use of two or more psychotropic medications to manage a mental and emotional condition. The prevalence of psychotropic polypharmacy has been increasing since the 1990s and has been attributed to the rise in multiple psychiatric conditions presenting in one patient. However, as the prevalence of polypharmacy increases to maximize therapeutic advantages, so does the adverse effect profile of those drugs used in combination, leading to very life-threatening effects such as agranulocytosis...
March 2024: Curēus
#7
JOURNAL ARTICLE
Yan Liang, Jing Liu, Jia Ge, Qiyun Shi, Guozhi Zhang, Andi Wan, Tao Luo, Hao Tian, Linjun Fan, Shushu Wang, Li Chen, Peng Tang, Kai Zhu, Jun Jiang, Xiuwu Bian, Yi Zhang, Xiaowei Qi
BACKGROUND: Anlotinib is a new type of tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1/2/3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1-4 and c-Kit, with a broad spectrum of inhibitory effects on tumor angiogenesis and growth. It has been proven effective in HER2-negative metastatic breast cancer, but its efficacy in early-stage triple-negative breast cancer (TNBC) is unknown. This phase 2 study aims to evaluate the efficacy and safety of adding anlotinib to neoadjuvant chemotherapy in patients with TNBC...
May 2024: EClinicalMedicine
#8
JOURNAL ARTICLE
Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Biliary tract cancer (BTC) is a highly aggressive malignancy with limited second-line therapy. We conducted this phase 2 trial to evaluate the efficacy and safety of second-line nab-paclitaxel plus sintilimab in advanced BTC. Histologically confirmed advanced BTC patients with documented disease progression after first-line chemotherapy were enrolled. Subjects received nab-paclitaxel 125 mg/m2 on days 1 and 8 plus sintilimab 200 mg on day 1, administered every 3 weeks. The primary end point was the objective response rate (ORR)...
April 18, 2024: Cancer Science
#9
JOURNAL ARTICLE
Zichen Qiu, Zheng Wu, Xiong Zhou, Minchuan Lin, Yong Su, Yalan Tao
PURPOSE: The objective of the study was to assess the effectiveness and toxicity of platinum-based adjuvant chemoradiotherapy (POCRT) in comparison to postoperative radiotherapy (PORT) in patients with head and neck adenoid cystic carcinoma (HNACC). MATERIALS AND METHODS: This retrospective study analyzed patients diagnosed with HNACC at our center between January 2010 and April 2020. A 1:1 propensity score matching method was used to create a matched cohort. RESULTS: In this study, 206 patients were analyzed, with 147 patients (71...
April 16, 2024: Journal of Cancer Research and Clinical Oncology
#10
JOURNAL ARTICLE
Makiko Go, Yoshihiro Noguchi, Rikuto Masuda, Hiroki Asano, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura
The most common toxicities associated with cyclin-dependent kinase (CDK) 4/6 inhibitor therapy include decreased leukopenia and neutropenia due to the inhibition of CDK6 of leukocyte and neutrophil precursors in bone marrow. These hematological toxicities are more commonly observed with palbociclib administration than with abemaciclib administration, which is approximately 13 times more selective against CDK4 than CDK6. Thus, even though both successfully inhibit CDK4/6, the side effects of palbociclib and abemaciclib differ due to differences in selectivity...
April 15, 2024: International Journal of Cancer. Journal International du Cancer
#11
JOURNAL ARTICLE
Jie Lin, Xiantao Lin, Rong Zheng, Kehai Lin, Muhammad Khan, Xiuting Huang, Yunhong Tian, Baiyao Wang, BenHua Xu, Yawei Yuan, Zhong Huang
The timing of radiotherapy (RT) delivery has been reported to affect both cancer survival and treatment toxicity. However, the association among the timing of RT delivery, survival, and toxicity in locally advanced nasopharyngeal carcinoma (LA-NPC) has not been investigated. We retrospectively reviewed patients diagnosed with LA-NPC who received definitive RT at multiple institutions. The median RT delivery daytime was categorized as morning (DAY) and night (NIGHT). Seasonal variations were classified into the darker half of the year (WINTER) and brighter half (SUMMER) according to the sunshine duration...
April 12, 2024: Chronobiology International
#12
JOURNAL ARTICLE
Chun Wang, Khushpreet Kaur, Canxin Xu, Yousef Abu-Amer, Gabriel Mbalaviele
Chemotherapy is a widely used treatment for a variety of solid and hematological malignancies. Despite its success in improving the survival rate of cancer patients, chemotherapy causes significant toxicity to multiple organs, including the skeleton, but the underlying mechanisms have yet to be elucidated. Using tumor-free mouse models, which are commonly used to assess direct off-target effects of anti-neoplastic therapies, we found that doxorubicin caused massive bone loss in wild-type mice, a phenotype associated with increased number of osteoclasts, leukopenia, elevated serum levels of danger-associated molecular patterns (DAMPs; e...
April 11, 2024: ELife
#13
JOURNAL ARTICLE
X R Chen, Z C Xie, H Z Lu, J L Yang, L Gui
Objective: To evaluate the efficacy and safety of pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC). Methods: This was a prospective, single-arm, open label, phase 2 clinical study enrolling patients at the Cancer Hospital of the Chinese Academy of Medical Sciences with R/M HNSCC treated with pembrolizumab plus nab-paclitaxel and cisplatin or carboplatin. After six cycles of treatment, patients received pembrolizumab as maintenance therapy until disease progression or intolerable toxicity or completion of 35 cycles of treatment...
April 8, 2024: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
#14
JOURNAL ARTICLE
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, Kyoichi Kaira, Toshiyuki Harada, Daizo Kishino, Yuichi Takiguchi, Tsuneo Shimokawa, Katsuyuki Kiura, Natsumi Yamashita, Hiroaki Okamoto
BACKGROUND: Bevacizumab with platinum doublet therapy including paclitaxel + carboplatin improves the survival of patients with non-squamous non-small cell lung cancer. However, in a previous trial (CA031), paclitaxel + carboplatin led to Grade > 3 neutropenia in a Japanese population. Nanoparticle albumin-bound paclitaxel exhibits an improved toxicity profile. We evaluated the safety, dosage and response rate of the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination in a Japanese population...
April 9, 2024: Japanese Journal of Clinical Oncology
#15
RANDOMIZED CONTROLLED TRIAL
Wen Li, Lan Ma, Fang Li, Kemin Li, Yang Zhang, Hongtao Ren, Xing Bao, Yuyan Guo, Ya Guo, Mincong Wang, Dan Li, Yuanqiong Duan, Xiulong Ma, Zhongwei Wang, Yali Wang, Rutie Yin
OBJECTIVE: To evaluate effects of bone marrow sparing (BMS) radiotherapy on decreasing the incidence of acute hematologic toxicity (HT) for locoregionally advanced cervical cancer (LACC) patients treated by pelvic irradiation. MATERIALS AND METHODS: LACC patients were recruited prospectively from May 2021 to May 2022 at a single center and were evenly randomized into the BMS group and the control group. All patients received pelvic irradiation with concurrent cisplatin (40 mg/m2 weekly), followed by brachytherapy and BM V40 < 25% in the BMS group was additionally prescribed...
April 9, 2024: Radiation Oncology
#16
JOURNAL ARTICLE
Urby Saraf Anika, Muna Islam, Fatema E Nur Mou, Mrinal Saha, Aparna Deb, Rubaiya Rahman Tui, Joarder Rakeen Manzoor, Afroza Jesmin, Ayesha Martuja, Jannatul Fardous, Mohiuddin Sharif, Md Abdur Rafi, Mohammad Jahid Hasan
For the past two decades, Bangladesh has faced recurrent dengue outbreaks, with the most recent occurring in 2023. We investigated the socioeconomic, clinical, and laboratory aspects of patients diagnosed with dengue during this outbreak. This observational study was conducted from July to September 2023 at Dhaka Medical College Hospital and Chittagong Medical College Hospital, and included 450 confirmed cases of dengue. Sociodemographic information was collected via face-to-face interviews, clinical examinations, and laboratory testing, which was done within 24 hours of admission...
April 9, 2024: American Journal of Tropical Medicine and Hygiene
#17
JOURNAL ARTICLE
Motoki Makuuchi, Yoichi Kakuta, Junji Umeno, Toshimitsu Fujii, Tetsuya Takagawa, Takashi Ibuka, Miki Miura, Yu Sasaki, Sakuma Takahashi, Hiroshi Nakase, Hiroki Kiyohara, Keiichi Tominaga, Yosuke Shimodaira, Sakiko Hiraoka, Nobuhiro Ueno, Shunichi Yanai, Takeo Yoshihara, Kazuki Kakimoto, Katsuyoshi Matsuoka, Ryohei Hayashi, Sohachi Nanjo, Itaru Iwama, Yoh Ishiguro, Hirofumi Chiba, Katsuya Endo, Takashi Kagaya, Tomohiro Fukuda, Yasuhisa Sakata, Takahiro Kudo, Tomohisa Takagi, Kenichi Takahashi, Makoto Naganuma, Masaru Shinozaki, Noriyuki Ogata, Hiroki Tanaka, Kazuyuki Narimatsu, Haruka Miyazaki, Takashi Ishige, Motoyuki Onodera, Yu Hashimoto, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Hisashi Shiga, Yoshitaka Kinouchi, Akira Andoh, Tadakazu Hisamatsu, Atsushi Masamune
BACKGROUND: This study evaluated the effectiveness of NUDT15 codon 139 genotyping in optimizing thiopurine treatment for inflammatory bowel disease (IBD) in Japan, using real-world data, and aimed to establish genotype-based treatment strategies. METHODS: A retrospective analysis of 4628 IBD patients who underwent NUDT15 codon 139 genotyping was conducted. This study assessed the purpose of the genotyping test and subsequent prescriptions following the obtained results...
April 8, 2024: Journal of Gastroenterology
#18
JOURNAL ARTICLE
Yuzhou Gan, Haotian Zhou, Yixue Guo, Bo Huang, Hongjiang Liu, Ziye Wang, Zijun Li, Xiaozhen Zhao, Huaqun Zhu, Qimao Han, Hua Ye, Jing He, Qingwen Wang, Zhanguo Li, Xiaolin Sun
OBJECTIVES: Glucocorticoid-induced Tumor-Necrosis-Factor-Receptor Family-related Protein (GITR), with its ligand (GITRL), plays an important role in CD4+ T-cell-mediated autoimmunity. This study aimed to investigate the underlying mechanisms of GITRL in primary Sjögren's Syndrome (pSS). METHODS: pSS patients and healthy controls were recruited. Serum GITRL and Th17-related cytokines were determinated. RNA-Sequencing was performed to decipher key signal pathways...
April 8, 2024: Arthritis & Rheumatology
#19
JOURNAL ARTICLE
Etienne J Slapak, Mouad El Mandili, Marieke S Ten Brink, Alexander Kros, Maarten F Bijlsma, C Arnold Spek
Pancreatic adenocarcinoma (PDAC) is highly resistant to conventional chemotherapeutic interventions, resulting in exceptionally low survival rates. The limited efficacy can in part be attributed to dose limitations and treatment cessation urged by toxicity of currently used chemotherapy. The advent of targeted delivery strategies has kindled hope for circumventing off-target toxicity. We have previously reported a PDAC-specific mesoporous silica nanoparticle (MSN) containing a protease linker responsive to ADAM9, a PDAC-enriched extracellularly deposited protease...
April 6, 2024: Cancer Letters
#20
JOURNAL ARTICLE
T M L Tong, M Fiocco, J J van Duijn-de Vreugd, J Lutjeboer, F M Speetjens, F G J Tijl, M E Sitsen, R W M Zoethout, C H Martini, A L Vahrmeijer, R W van der Meer, C S P van Rijswijk, A R van Erkel, E Kapiteijn, M C Burgmans
PURPOSE: Percutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP. MATERIALS AND METHODS: A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver...
April 8, 2024: Cardiovascular and Interventional Radiology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
